Best Places to Work

Found 10,157 articles

• Sutro Biopharma to Present at the JMP Securities Life Sciences Conference - May 08, 2023

  5/8/2023

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.

• Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's Plan

  5/8/2023

  Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter highlighting the strength of its Board and noting that Carl Icahn's "plan" for Illumina is sloppy and uninformed.

• CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

  5/8/2023

  CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.

• Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

  5/8/2023

  Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.

• AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

  5/6/2023

  AbbVie announced it will present 29 abstracts during the 2023 Digestive Disease Week Annual Meeting, May 6-9, 2023, being held in Chicago and virtually.

• Nexus Pharmaceuticals, Inc. Receives Successful FDA Inspection of Pharmaceutical Manufacturing Facility in Pleasant Prairie, Wisconsin

  5/5/2023

  Nexus Pharmaceuticals, Inc. announced that its pharmaceutical manufacturing facility in Pleasant Prairie, Wisconsin, was successfully inspected by the Food and Drug Administration, which will allow Nexus to begin commercial operations.

• 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - May 05, 2023

  5/5/2023

  4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced that it priced an upsized underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share.

• MODERNA AND NOVOCOL PHARMA ANNOUNCE FILL-FINISH AGREEMENT FOR CANADIAN-MADE MRNA VACCINES

  5/4/2023

  Moderna, Inc. (NASDAQ: MRNA) today announced a long-term agreement with Ontario-based Novocol Pharma, a leading sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada.

• Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

  5/4/2023

  Silence Therapeutics plc today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program.

• CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)

  5/4/2023

  CHMP Adopts Positive Opinion Recommending Hepcludex ® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV).

• Bayer Opens First Co.Lab Life Science Incubator in Cambridge

  5/4/2023

  Bayer AG announced the inauguration of its new life science incubator dubbed “Co.Lab Cambridge” located in Kendall Square in Cambridge, U.S. Bayer’s Co.Lab Cambridge is specifically designed to support cutting-edge cell and gene therapies entrepreneurs with access to Bayer’s enterprise wide expertise in addition to state-of-the-art laboratory and office space.

• Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

  5/4/2023

  Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reported financial results and provided business updates for the first quarter of 2023.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023

  5/4/2023

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 34,000 shares, and restricted stock units covering an aggregate of 23,800 shares, of BioCryst common stock.

• 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock - May 04, 2023

  5/4/2023

  4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.

• Regeneron Reports First Quarter 2023 Financial and Operating Results

  5/4/2023

  Regeneron Pharmaceuticals, Inc. announced financial results for the first quarter of 2023 and provided a business update.

• BioMarin to Participate in Bank of America 2023 Health Care Conference

  5/4/2023

  BioMarin Pharmaceutical Inc. announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:40pm PT, in Las Vegas, NV.

• Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

  5/4/2023

  Amphista Therapeutics today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.

• Capital Health Recertified as Level II Trauma Center

  5/3/2023

  The Bristol Myers Squibb Trauma Center at Capital Health Regional Medical Center has been recertified as a Level II Trauma Center by the Committee on Trauma of the American College of Surgeons.

• ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab

  5/3/2023

  The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eli Lilly and Company for their amyloid-clearing antibody donanemab.

• Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

  5/3/2023

  The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination.